Drug General Information (ID: DDIB9NQIXU)
Drug Name			Dolasetron		Drug Info		Penbutolol		Drug Info
Drug Type		Small molecule				Small molecule
Therapeutic Class		Antiemetics				Antihypertensive Agents
Structure

Mechanism of Dolasetron-Penbutolol Interaction (Severity Level: Major)
Increased risk of atrioventricular block Click to Show/Hide Mechanism Graph
Drug Name		Dolasetron				Penbutolol
Mechanism		Delay atrioventricular conduction				Delay atrioventricular conduction
Key Mechanism Factor 1
		Factor Name		Atrioventricular block
		Factor Description		Atrioventricular block is a type of cardiac conduction block that occurs when the electrical signal from the atria to the ventricles is impaired. In an Atrioventricular block, this electrical signal is either delayed or completely blocked. When the signal is completely blocked, the ventricles produce their own electrical signal to control the heart rate. The heart rate produced by the ventricles is much slower than that produced by the sinus node.
Mechanism Description		Increased risk of atrioventricular block by the combination of Dolasetron and Penbutolol

Recommended Action
Management		Caution is advised if dolasetron is used concomitantly with other agents that prolong the PR or QRS interval, especially in the elderly and patients with known risk factors. An ECG should be obtained in these patients before initiating dolasetron and periodically during treatment. Patients should be advised to notify their physician if they experience dizziness, lightheadedness, fainting, or irregular heartbeat. Dolasetron should be avoided in patients with complete heart block or at risk for complete heart block, unless they have an implanted pacemaker.

References
1	Product Information. Anzemet (dolasetron). Hoechst Marion-Roussel Inc, Kansas City, MO.